In previous clinical studies in Asia, TAS-117 has shown clinical efficacy in PIK3CA-mutated endometrial and ovarian cancers, in breast cancer cases harboring PIK3CA or AKT1 mutations, and in patients with ovarian clear cell carcinoma. Here, AKT1 is linked to breast cancer.